Search Bar & Filters
Found 17 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
Researchers are studying the effects of orforglipron compared to a placebo in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This Phase 3 trial aims to evaluate how orforglipron impacts major cardiovascular events over about five years of participation. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally with standard care. The study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. This design helps measure the drugs impact on cardiovascular health and kidney function over the study duration. During the study, participants will be monitored regularly to track the time to the first major cardiovascular event and other health outcomes such as kidney function changes and the onset of type 2 diabetes. The study involves ongoing assessments from baseline through the five-year period, including follow-ups to ensure safety and gather detailed health information.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tacabrutideg compared with pirtobrutinib in adults with relapsed or refractory chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL who have previously been treated with a covalent Bruton tyrosine kinase inhibitor cBTKi. This phase 3, open-label, randomized study focuses on patients whose disease has relapsed or not responded after at least one line of therapy including a cBTKi. Participants will be randomly assigned to receive either tacabrutideg or pirtobrutinib, both given orally. The study compares the two drugs in parallel groups to assess their safety and efficacy over the course of treatment. During the study, participants will be closely monitored for disease progression, survival, response rates, duration of response, time to next treatment, adverse events, and quality of life using standardized questionnaires. These assessments will be conducted for up to approximately 3 years to evaluate the long-term outcomes and safety profiles of the treatments.
Actively Recruiting
Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.
Actively Recruiting
Researchers are evaluating the optimization of implant positioning in Reverse Shoulder Arthroplasty, comparing Exactech Guided Personalized Surgery GPS with conventional instrumentation techniques. The study aims to assess how the implant position affects the range of motion and patient-reported outcomes. This is a prospective, multi-center, randomized clinical study sponsored by Exactech with a long-term follow-up of up to 10 years and a minimum follow-up of 2 years for patients. Participants will undergo Reverse Shoulder Arthroplasty using either the Exactech GPS system or conventional methods. The study tracks implant positioning accuracy and compares the two techniques. There are no specific interventions detailed beyond the surgical methods being compared. Patients will be followed for a minimum of 2 years with assessments continuing through study completion, which may last up to 10 years. During the study, participants will be assessed regularly using several patient-reported outcome measures including SST-12, SPADI, Constant, ASES, and UCLA scores. These evaluations occur approximately once per year throughout the study duration. Participants must comply with pre- and postoperative visit requirements and undergo a preoperative CT scan within three months before surgery. Safety and functional outcomes will be monitored throughout the follow-up period.
Actively Recruiting
Researchers are evaluating two surgical methods of distal gastric bypass DGB as revisional surgery for patients who have had insufficient weight loss or weight regain after Roux-en-Y gastric bypass RYGB. This multicenter randomized controlled trial aims to determine which DGB technique is better for total weight loss and managing protein calorie malnutrition. The study involves morbidly obese patients eligible for distalisation surgery, addressing a gap in consensus for optimal surgical approaches after failed RYGB. Participants will be randomly assigned to one of two groups DGB type I, which involves lengthening the biliopancreatic limb by modifying the Roux limb and reattaching it further along the intestine, or DGB type II, which lengthens the alimentary limb by dividing and reattaching the biliopancreatic limb. Both procedures are performed laparoscopically. The trial includes follow-up visits at 1.5, 3, 6, 12, 18, 24, and 36 months after surgery to monitor outcomes. During the study, participants will undergo regular clinical and outpatient assessments including weight measurements, evaluation of protein calorie malnutrition, defecation patterns, nutritional deficiencies, and quality of life questionnaires. Researchers will track weight loss and malnutrition treatment needs primarily at one year post-surgery, with additional secondary outcomes assessed up to three years. Patient satisfaction and eating behavior will also be evaluated throughout the follow-up period. The total participation spans up to three years to thoroughly assess long-term effects and safety.
Actively Recruiting
Researchers are evaluating chemotherapy dosing strategies in older patients aged 70 years and above who have metastatic colorectal cancer and are eligible for first-line palliative chemotherapy. This phase III randomized controlled trial aims to compare upfront dose-reduced chemotherapy with standard full-dose chemotherapy, focusing on progression-free survival PFS. Patients are assessed using the Geriatric 8 G8 questionnaire to determine their risk of chemotherapy toxicity, which guides treatment assignment. The study seeks to balance treatment effectiveness with minimizing toxicity, hospital admissions, and maintaining quality of life QoL and physical functioning. Participants classified as low risk for toxicity G8 score 15 or higher are randomized to receive either doublet chemotherapy a fluoropyrimidine combined with oxaliplatin at full dose or with a 25% dose reduction upfront. Those at high risk G8 score 14 or lower or judged high risk by their oncologist receive fluoropyrimidine monotherapy either at full dose or with a 25% dose reduction. The study also allows the addition of targeted treatments like bevacizumab or EGFR inhibitors. Dose adjustments are made for patients with moderate kidney impairment. Chemotherapy is given orally or intravenously on schedules varying between every two and three weeks, depending on the regimen. Participants will be closely monitored throughout treatment, with assessments including radiological or clinical evaluations for disease progression, quality of life and physical functioning questionnaires at 1, 3, 6, and 12 months, and tracking of chemotherapy toxicity, overall survival, treatment cycles, dose changes, hospital admissions, and cumulative drug dosage. Safety and cost-effectiveness will also be evaluated over an average study duration of eight months and up to one year for some outcomes. The study plans to include 587 patients and will continue until December 2028.
Actively Recruiting
This research aims to evaluate individualized thrombosis prevention after total hip or knee replacement surgery. Despite standard blood thinner treatment given to all patients to prevent venous thromboembolism VTE, some still develop clots while others experience bleeding. The study investigates whether customizing the type and duration of blood thinner treatment based on each patients medical history can reduce both clotting and bleeding risks compared to the standard uniform approach. Participants are grouped by their predicted VTE risk using the TRiPplasty score into low, intermediate, or high risk. Low-risk patients are randomized to receive either standard prophylaxis or a shortened treatment only during hospital stay. High-risk patients are randomized to receive standard treatment or a higher dose for six weeks. Intermediate-risk patients are observed without treatment changes. Blood thinners used include types of LMWH or DOACs given according to local standards, with dosing timing specified after surgery. Participants complete four questionnaires one before surgery and follow-ups at 2 weeks, 6 weeks, and 3 months post-surgery to report any VTE or bleeding events. An additional questionnaire is sent one year after surgery if certain complications occurred, assessing quality of life and joint function. No extra hospital visits are required. The main outcomes measured are symptomatic VTE and major bleeding within 90 days post-surgery, along with other health and quality of life measures up to one year.
Actively Recruiting
Researchers are evaluating whether low-dose colchicine, an anti-inflammatory drug, can reduce the risk of serious vascular events in patients with symptomatic peripheral artery disease PAD. This study is a randomized, double-blind, multicenter trial involving 6,150 participants, aiming to prevent events such as heart attack, stroke, cardiovascular death, severe limb ischemia, and major vascular amputation. The primary outcome measured is a combination of major adverse cardiovascular and limb events MACE and MALE. Participants are randomly assigned to receive either colchicine 0.5 mg once daily or a placebo that looks identical. The trial includes an active run-in period and will continue over a period of 3 to 5 years, during which patients take their assigned tablets daily. Both the active drug and placebo are stored securely and administered under blinded conditions so neither patients nor investigators know which treatment is given. Throughout the study, participants will be regularly monitored for cardiovascular events and limb health. Evaluations include tracking occurrences of heart attacks, strokes, hospitalization, vascular interventions, amputations, and mortality. Quality of life and physical activity are also assessed using specific questionnaires. Safety monitoring and follow-up will continue for the duration of the trial, which may last up to 5 years for each participant.
Actively Recruiting
Phase 3 Randomized Trial Comparing Re-excision to No Re-excision After Primary Skin Melanoma Removal
Researchers are investigating whether skipping the usual follow-up surgery called re-excision after removing primary cutaneous melanoma affects patient outcomes. This large, phase III trial involves 1,749 patients with melanoma stages pT1b to pT4b who have no signs of metastases. The study compares relapse-free survival between those who receive standard re-excision and those who do not, while also examining overall survival, recurrence rates, surgical side effects, quality of life, and economic impact. Participants are randomly assigned to either undergo re-excision surgery with margins of 1 to 2 centimeters according to local guidelines or to receive no further surgery after the initial tumor removal. Sentinel lymph node biopsy and additional systemic treatments are given as needed in both groups. Re-excision, if performed, occurs within 12 weeks of the first surgery and follows standardized procedures to ensure clear margins. Patients will be monitored for up to five years to track recurrence and other outcomes. During the study, patients will have regular follow-ups including assessments of cancer recurrence, surgical complications, and quality of life using validated questionnaires at various time points up to two years. Health economic data will also be collected to evaluate cost-effectiveness. The main measure is relapse-free survival over five years, with additional measures including overall survival and different types of melanoma recurrence. Safety and quality of life are carefully tracked, with management of recurrences left to treating physicians throughout the study period.
1-10 of 17
1